Management/Directors/SAB

Dr. Louis Lange is a founder of CV Therapeutics and has served as the Chairman of the Board and Chief Executive Officer since August 1992. From 1980 to 1992, Dr. Lange served on the faculty of the Washington University School of Medicine, including a position as Chief of Cardiology at the Jewish Hospital in St. Louis, Missouri, from 1985 to 1992, and as a full Professor of Medicine from 1990 until 1992.

Dr. Lange is internationally recognized as an expert in the field of molecular mechanisms of cardiovascular disease. He is currently on the Board of Trustees at the University of Rochester. He also serves on the Executive Committee of the Biotechnology Industry Organization (BIO), as well as the BIO Board of Directors, and he is chair of the Emerging Companies Governing Section. Dr. Lange holds an MD from Harvard Medical School and a PhD in biochemistry from Harvard University.

Mr. David Banks joined CVT in 2007 as Senior Vice President of Operations. He has more than 20 years of operations experience in the pharmaceutical industry having helped launch new products, expand organizations to support rapidly growing businesses, improve organizational effectiveness, and manage strategic alliances. He was previously with Johnson & Johnson where he held positions as Vice President of Consumer Alliance Management, responsible for the pharmaceutical supply chain for J&J's Consumer Division, and as Vice President of Manufacturing, leading a 700-person organization that manufactured controlled-release pharmaceuticals and drug/device combinations.

From 1995 to 2001, Mr. Banks worked for ALZA Corporation, in positions of increasing responsibility including Vice President of Manufacturing, where he was instrumental in improving organizational performance and building capabilities to launch several successful products. Mr. Banks has also worked for Syntex where he led functional groups in logistics, technical services, and manufacturing.

Mr. Banks received his MBA from East Tennessee State University and his BS in industrial engineering from Tennessee Tech University.

Dr. Luiz Belardinelli is Senior Vice President of Pharmacology and Translational Biomedical Research and a Distinguished Fellow of Cardiovascular Science. Before joining CV Therapeutics in 1999, Dr. Belardinelli was Professor of Medicine in the Divisions of Cardiology and Pharmacology at the University of Florida, where he was the Eminent Scholar Chair in Cardiovascular Research. Dr. Belardinelli has helped elucidate the mechanism of action of late sodium current inhibition, defined the role of cardiac adenosine receptor subtypes, and pioneered the use of adenosine in the treatment of supraventricular tachycardia.

Internationally recognized as an expert in adenosine physiology and pharmacology, Dr. Belardinelli has received awards such as the Inventor of the Year Award from the University of Virginia (1992), the Dr. Harold Lamport Award of the American Physiology Society Cardiovascular Section (1984), and the Young Investigator Award of the 11th Interamerican Congress of Cardiology (1980). He has authored over 160 journal articles and book chapters and more than 20 U.S. patents.

Dr. Belardinelli received his MD from the Medical Catholic School of Pôrto Alegre, Brazil and completed a four-year postdoctoral research fellowship in the Department of Physiology at the University of Virginia.

Dr. Brent Blackburn has served as Senior Vice President for Drug Discovery and Development at CV Therapeutics since January 2004. He also served as Senior Vice President for Drug Discovery and Preclinical Development (2002-2004) and Vice President for Developmental Research (2000-2002). At Genentech, Inc., Dr. Blackburn was part of the Research Department (1989-1997) and project team leader for a cardiovascular product in the Development Department (1993-1997).

Dr. Blackburn holds a BS in chemistry from Texas Christian University and a PhD in chemistry from the University of Texas, Austin. He completed postdoctoral research fellowships in the departments of chemistry at Oxford University and the Massachusetts Institute of Technology.

Ms. Carol Karp is Senior Vice President for Regulatory Affairs, Quality, and Drug Safety at CV Therapeutics. She has over 25 years of experience in regulatory affairs, project management, compliance, and quality assurance in the pharmaceutical industry. Before joining CV Therapeutics, she was Vice President of Scientific Affairs at PowderJect Technologies. Ms. Karp has held previous positions as a corporate officer at VIVUS, Inc. and established the regulatory affairs function at Cygnus, Inc., a transdermal drug delivery company, where she was the project leader for EVRA^®, the first oral contraceptive patch co-developed with Johnson & Johnson. Ms. Karp began her career in regulatory affairs at Janssen Pharmaceutica, a Johnson & Johnson company, where she managed the approval process for several new drug applications.

Ms. Karp received her bachelor's degree in biology from the University of Rochester and pursued graduate studies at New York University.

Ms. Diane Liguori joined CV Therapeutics in 1995 and is an integral member of the senior management and the international and business operations teams. She has led the human resources team for the past ten years, helping the company manage its growth and commercial transformation in concert with clinical and regulatory progress. Ms. Liguori led the effort to establish and staff a European subsidiary in December 2002 and is at the helm of the employment team that most recently managed the addition of US field-based sales and medical information teams.

Ms. Liguori is an active member of the Bay Area Senior Human Resources Group, a consortium of life sciences human resources professionals that collectively addresses leadership challenges in the biopharmaceutical industry. For the past twenty years, Ms. Liguori has held increasingly senior roles in the Bay Area in both marketing and human resources.

Ms. Liguori holds a BS in biology from The College of William & Mary.

Mr. John Mohr is Senior Vice President of Business Development. He has over 20 years of industry experience in the life-science area. Previously, he held senior executive positions in corporate development with several bio-pharma companies including Topigen, Atherogenics and Perrigo. He was former Head of US Operations for Fournier Pharma responsible for US commercial and development activities, including the successful partnering and introduction of TriCor®, a billion dollar cardiovascular agent. Prior experience includes executive management positions at Merck. including worldwide responsibility for marketing for Pepcid®. Mr. Mohr has substantial experience in managing and licensing bio-pharma technologies as both operating executive and commercial strategist. He currently serves as a member of the Business Development Roundtable for the Biotechnology Council of New Jersey and a member of the Licensing Executive Society.

Mr. Mohr holds a BS in finance/accounting from Drexel University and is a Certified Public Accountant and Licensing Professional.

Mr. Daniel Spiegelman has served as Senior Vice President and Chief Financial Officer of CV Therapeutics since September 1999. He also served as Vice President and Chief Financial Officer from January 1998 to September 1999. From 1991 until 1998, he was employed by Genentech, Inc., holding various positions in the treasury department, including the position of Treasurer from 1996 to 1998. Mr. Spiegelman is a member of the board of directors of Cyclacel Pharmaceuticals and Affymax Inc.

Mr. Spiegelman holds a BA in economics from Stanford University and an MBA from the Stanford Graduate School of Business.

Mr. Lewis Stuart is Senior Vice President of Commercial Operations. He has more than 25 years of sales and marketing experience. Since 1990, he has held senior U.S. and European sales and marketing positions within the biotechnology sector, including six years as vice president, sales, at Agouron Pharmaceuticals, Inc., a Pfizer company. There, he fielded an HIV sales organization to launch Agouron's lead product, Viracept^®, which became the most widely prescribed protease inhibitor in the U.S. Earlier in Mr. Stuart's career, he directed the sales teams for several cardiovascular products at Bristol Myers Squibb, Inc., including Capoten^®, an ACE inhibitor prescribed to treat high blood pressure and congestive heart failure, and Corgard^®, a beta-blocker prescribed to treat angina and high blood pressure.

Mr Stuart holds a BA in Marketing Communications from Virginia Tech (VPISU).

Ms. Tricia Suvari is Senior Vice President, General Counsel and Secretary of CV Therapeutics, Inc. She has been with CV Therapeutics since May 2000. From 1991 until 2000, Ms. Suvari was employed by Genentech, Inc., holding various positions in the legal department. From 1988 until 1991, Ms. Suvari was employed by the law firm Irell & Manella LLP in Los Angeles, CA.

Ms. Suvari holds a BS in geology and geophysics from Yale College and a JD from Harvard Law School.